HIV-specific and other clinical indicators among LHIV-Manitoba cohort participants, by sex
| Male* (N=634) | Female* (N=256) | Total* (N=890) | P value | ||||
| n | % | n | % | n | % | ||
| Initial CD4 count in Manitoba (cells/mm3) | |||||||
| <200 | 211 | 33.8 | 72 | 28.7 | 283 | 32.3 | 0.467 |
| 200–350 | 151 | 24.2 | 65 | 25.9 | 216 | 24.7 | |
| 351–500 | 117 | 18.8 | 47 | 18.7 | 164 | 18.7 | |
| >500 | 145 | 23.2 | 67 | 26.7 | 212 | 24.2 | |
| Mean (SD) | 328.2 (248.7) | 370.5 (257.1) | 340.3 (251.7) | ||||
| Median (IQR) | 298.5 (116–478.5) | 336 (179–517) | 316 (129–492) | ||||
| Last CD4 count, up to the end of 2018 (cells/mm3) | |||||||
| <200 | 81 | 12.8 | 47 | 18.6 | 128 | 14.5 | 0.064 |
| 200–350 | 88 | 14.0 | 38 | 15.0 | 126 | 14.3 | |
| 351–500 | 130 | 20.6 | 38 | 15.0 | 168 | 19.0 | |
| >500 | 332 | 52.6 | 130 | 51.4 | 462 | 52.3 | |
| Mean (SD) | 589.3 (303.6) | 331.7 (302.0) | 542.2 (319.1) | ||||
| Median (IQR) | 565 (384–768) | 256 (99–472) | 517.5 (309.5–735.5) | ||||
| Initial viral load (copies/mL) | |||||||
| <200 | 329 | 54.7 | 100 | 40.3 | 429 | 50.5 | 0.001† |
| 200–999 | 27 | 4.5 | 16 | 6.5 | 43 | 5.1 | |
| 1000–99 999 | 147 | 24.5 | 90 | 36.3 | 237 | 27.9 | |
| 100 000–999 999 | 80 | 13.3 | 36 | 14.5 | 116 | 13.7 | |
| ≥1 000 000 | 18 | 3.0 | 6 | 2.4 | 24 | 2.8 | |
| Mean (SD) | 125 778.7 (523 975.9) | 107 972 (340 114.2) | 120 577.2 (477 511.4) | ||||
| Median (IQR) | 60.9 (0–38 400) | 1875 (0–40 300) | 170 (0–38 800) | ||||
| Last viral load, up to the end of 2018 (copies/mL) | |||||||
| <200 | 491 | 84.4 | 190 | 80.2 | 681 | 83.2 | 0.517† |
| 200–999 | 22 | 3.8 | 9 | 3.8 | 31 | 3.8 | |
| 1000–99 999 | 46 | 7.9 | 28 | 11.8 | 74 | 9.0 | |
| 100 000–999 999 | 18 | 3.1 | 8 | 3.4 | 26 | 3.2 | |
| ≥1 000 000 | 5 | 0.9 | 2 | 0.8 | 7 | 0.9 | |
| Mean (SD) | 40 972 (415 359.2) | 27 705 (171 693.3) | 37 133.2 (362 048.3) | ||||
| Median (IQR) | 0 (0–27.9) | 0 (0–54.6) | 0 (0–32.4) | ||||
| Opportunistic infections (OI)ठ| |||||||
| None | 364 | 69.9 | 150 | 73.5 | 514 | 70.9 | 0.131† |
| Oropharyngeal and/or oesophageal candidiasis (thrush) | 108 | 20.7 | 39 | 19.1 | 147 | 20.3 | |
| Pneumocystis jirovecii pneumonia | 56 | 10.8 | 9 | 4.4 | 65 | 9.0 | |
| Active tuberculosis | 29 | 5.6 | 14 | 6.9 | 43 | 5.9 | |
| Mycobacterium avium intracellulare | 7 | 1.3 | 1 | 0.5 | 8 | 1.1 | |
| Cryptococcal meningitis | 4 | 0.8 | 1 | 0.5 | 5 | 0.7 | |
| Hepatitis C virus status at cohort enrolment | |||||||
| No infection | 496 | 78.2 | 182 | 71.1 | 678 | 76.2 | 0.085† |
| Active infection (RNA+) | 105 | 16.6 | 51 | 19.9 | 156 | 17.5 | |
| Past infection (RNA−/Ab+) | 32 | 5.1 | 22 | 8.6 | 54 | 6.1 | |
| Unknown | 1 | 0.2 | 1 | 0.4 | 2 | 0.2 | |
| Comorbiditiesঠ| |||||||
| None | 305 | 58.5 | 125 | 61.3 | 430 | 59.3 | 0.006† |
| Asthma/Chronic obstructive pulmonary disease (COPD) | 93 | 17.9 | 36 | 17.7 | 129 | 17.8 | |
| Hypertension | 88 | 16.9 | 24 | 11.8 | 112 | 15.5 | |
| Type II diabetes | 66 | 12.7 | 39 | 19.1 | 105 | 14.5 | |
| Coronary artery disease | 33 | 6.3 | 3 | 1.5 | 36 | 5.0 | |
*Sample sizes may not add up to total participants due to missing data for some variables.
†Some expected values <5, so p values must be interpreted with caution.
‡Variable only collected for participants who were alive at cohort enrolment: male, n=521; female, n=204 and total, n=725.
§Diagnosed at, or within 6 months of presentation to care with the Manitoba HIV Program. Sum of categories exceeds total sample size because some participants presented with ≥1 OI.
¶Sum of categories exceeds total sample size because some participants presented with ≥1 comorbidity.